Flash Finance

Ajanta Pharma LimitedAJANTPHARMCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹3,329.00
MCap ₹41,599 Cr · P/E 41.3
Ajanta Pharma Limited — Stock analysis & AI research Ajanta Pharma Limited — Multibagger AI analysis Ajanta Pharma Limited — Seasonality — best & worst months Ajanta Pharma Limited — Technical indicators & charts Ajanta Pharma Limited — Technical setup — score, trend, support & resistance Ajanta Pharma Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks With Strong Quarterly Results📋 Low Debt Stocks ⚖️ vs Torrent Pharmaceuticals⚖️ vs Gland Pharma 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,489 Cr
Sales · Jun 2026
+23.2% YoY
₹397 Cr
Operating Profit · Jun 2026
+20.4% YoY
26.6%
OPM % · Jun 2026
-2.6% YoY
₹315 Cr
Net Profit · Jun 2026
+23.7% YoY
₹25.25
EPS · Jun 2026
+23.7% YoY

📝 Ajanta Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Ajanta Pharma Limited reported revenue of ₹1,489 crore for the quarter ended June 2026 (Q1 FY27), up 23.2% from ₹1,209 crore in the same quarter last year, and up 22.9% sequentially over the March 2026 quarter.

Net profit rose 23.7% year-on-year to ₹315 crore, from ₹255 crore. Earnings per share (EPS) came in at ₹25.25.

Operating profit stood at ₹397 crore — an operating margin (OPM) of 26.6%, compared with 27.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Ajanta Pharma Limited posted revenue of ₹4,846 crore, a growth of 12.1% over FY25, with a net profit of ₹947 crore (up 3.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹5,126 crore with a net profit of ₹1,007 crore.

Valuation snapshot

At the current price of ₹3,329.00, AJANTPHARM has a market capitalisation of ₹41,599 crore and a trailing P/E of about 41.3.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 16th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 63.47%, foreign institutional investors (FIIs) 7.63%, domestic institutional investors (DIIs) 21.94%, public shareholders 6.96% of Ajanta Pharma Limited.

Promoter holding slipped from 66.25% to 63.47% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹41,599 Cr
Current Price ?
₹3,329.0
P/E ?
41.31above ind
Industry P/E ?
35.00
P/B ?
9.85
P/S ?
8.11
P/FCF ?
95.19
Enterprise Value ?
₹41,634 Cr
EV/EBITDA ?
32.91
PEG ?
2.07
Earnings Yield ?
2.6%
Dividend Yield ?
0.85%
Profitability & Returns
Sales (TTM) ?
₹5,126 Cr
OPM ?
24.7%
Profit after tax (TTM) ?
₹1,007 Cr
EPS (TTM) ?
₹80.59
ROCE ?
31.0%
ROE ?
23.8%
ROA ?
18.9%
Growth
Sales — latest qtr ?
₹1,489 Cr
PAT — latest qtr ?
₹315 Cr
YoY qtr sales growth ?
23.2%
YoY qtr profit growth ?
23.7%
Sales growth (3y) ?
12%
Sales growth (5y) ?
12%
Profit growth (3y) ?
20%
Profit growth (5y) ?
7%
Financial Health
Debt ?
₹35 Cr
Debt to Equity ?
0.01
Interest Coverage ?
441.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
63.47%
Change in promoter holding ?
-2.79%
Pledged percentage ?
N/A
Market
Return 3 months ?
-2.6%
Return 6 months ?
19.3%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 8758491,0159451,0859261,0771,1291,1021,0141,2091,2201,2071,2111,489 +23.2% +22.9%
Operating Profit 159145277274327227316303336250329290341238397 +20.4% +66.7%
Other Income 313731521434284033184175266371 +74.3% +12.4%
Interest 3112211121112-11 +4.1% +176.0%
Depreciation 323232333333333335394042424443 +7.4% -1.6%
Profit Before Tax 155148275290305226311309332228329322322258423 +28.7% +64.1%
Net Profit 124117212212220163236235252193255250245197315 +23.7% +60.1%
EPS 9.679.1516.8416.8717.4812.9218.7718.7520.1615.4620.4119.9819.6115.7925.25 +23.7% +59.9%
OPM % 18.2% 17.0% 27.3% 29.0% 30.1% 24.5% 29.3% 26.8% 30.5% 24.6% 27.3% 23.7% 28.3% 19.7% 26.6% -2.6% +35.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹4,322 Cr ₹4,846 Cr ₹5,126 Cr +12.1%
Operating Profit ₹1,205 Cr ₹1,198 Cr ₹1,265 Cr -0.6%
OPM % 27.87% 24.72% 24.68% -11.3%
NPM % 21.21% 19.53% 19.64% -7.9%
Other Income ₹120 Cr ₹204 Cr ₹235 Cr +70.5%
Depreciation ₹140 Cr ₹169 Cr ₹172 Cr +20.5%
Interest ₹5 Cr ₹2 Cr ₹2 Cr -49.3%
EBIT ₹1,065 Cr ₹1,029 Cr ₹1,094 Cr -3.3%
PBT ₹1,180 Cr ₹1,231 Cr ₹1,326 Cr +4.4%
Tax ₹263 Cr ₹224 Cr ₹258 Cr -14.9%
Net Profit ₹917 Cr ₹947 Cr ₹1,007 Cr +3.2%
EPS ₹73.14 ₹75.79 ₹80.63 +3.6%
Material Cost ₹1,031 Cr ₹820 Cr ₹926 Cr -20.5%
Employee Cost ₹1,011 Cr ₹881 Cr ₹952 Cr -12.9%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 25252525 +0.0%
Reserves 3,2213,3883,6004,198 +16.6%
Borrowings 33313135 +12.9%
Other Liabilities 1,0257738981,058 +17.8%
Total Liabilities 4,3054,2174,5545,317 +16.8%
Fixed Assets 1,4841,4651,7421,845 +5.9%
CWIP 209256176258 +46.6%
Investments 553367482606 +25.7%
Other Assets 2,0582,1292,1542,608 +21.1%
Total Assets 4,3054,2174,5545,317 +16.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 7367351,054804 -23.7%
Cash from Investing Activity -501105-350-400 -14.3%
Cash from Financing Activity -105-1,048-716-360 +49.7%
Net Cash Flow 130-207-1245 +475.0%
Free Cash Flow 561595737437 -40.7%
CFO/OP 123%88%111%92% -17.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 105111104103 -1.0%
Inventory Days 248229267286 +7.1%
Days Payable 128130132160 +21.2%
Cash Conversion Cycle 225210238229 -3.8%
Working Capital Days 92130116161 +38.8%
ROCE % 21%32%33%31% -6.1%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 66.26%66.25%66.25%66.25%63.47% -4.2%
FIIs 8.86%8.53%7.97%8.26%7.63% -7.6%
DIIs 17.50%17.90%18.58%18.36%21.94% +19.5%
Government 0.01%0.01%0.01%0.01%— —
Public 7.38%7.32%7.20%7.14%6.96% -2.5%
No. of Shareholders 68,88267,78565,40967,95561,923 -8.9%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Ajanta Pharma Limited's revenue in Q1 FY27?
Ajanta Pharma Limited reported revenue of ₹1,489 crore for the quarter ended June 2026 (Q1 FY27), up 23.2% from ₹1,209 crore in the same quarter last year, and up 22.9% sequentially over the March 2026 quarter.
What was Ajanta Pharma Limited's net profit in Q1 FY27?
Net profit rose 23.7% year-on-year to ₹315 crore, from ₹255 crore. Earnings per share (EPS) came in at ₹25.25.
What is AJANTPHARM's market capitalisation and P/E ratio?
At the current price of ₹3,329.00, AJANTPHARM has a market capitalisation of ₹41,599 crore and a trailing P/E of about 41.3.
Who owns Ajanta Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 63.47%, foreign institutional investors (FIIs) 7.63%, domestic institutional investors (DIIs) 21.94%, public shareholders 6.96% of Ajanta Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI